News >

Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up

Jason M. Broderick @jasoncology
Published: Tuesday, Dec 20, 2016

Maria-Victoria Mateos, MD, PhD

Maria-Victoria Mateos, MD, PhD

The benefits of 2 FDA-approved daratumumab (Darzalex)–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.1,2

At the recent ASH meeting, CASTOR and POLLUX updates were presented, respectively, by Maria-Victoria Mateos, MD, PhD, consultant physician, hematology department, Hospital Universitario de Salamanca, and Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System.


The CASTOR study randomized 498 patients with relapsed or refractory multiple myeloma to bortezomib and dexamethasone alone (n = 247) or with daratumumab (n = 251). Patients had received a median of 2 prior lines of therapy. Overall, 66% had received prior bortezomib, 76% received a prior immunomodulatory drug (IMiD), and 48% had received prior proteasome inhibitors and IMiD. The median age was 64 years (range, 30-88).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication